Lobe Sciences (FRA:LOBE) EPS (Basic): €-0.02 (TTM As of Feb. 2026)


What is Lobe Sciences EPS (Basic)?

Lobe Sciences FRA:LOBE EPS (Basic) is €-0.02 as of Feb. 2026. The stock has 2 warning signs investors should review.

Lobe Sciences's basic earnings per share (Basic EPS) for the three months ended in Feb. 2026 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.02.

Lobe Sciences's EPS (Diluted) for the three months ended in Feb. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 was €-0.02.

Lobe Sciences's EPS without NRI for the three months ended in Feb. 2026 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2026 was -0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Lobe Sciences  (FRA:LOBE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lobe Sciences EPS (Basic) Related Terms

Lobe Sciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences EPS (Basic) Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.25 -0.03 -0.03 -0.02

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.01 -0.01 -0.01 -0.01

Lobe Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lobe Sciences's Basic EPS for the fiscal year that ended in Aug. 2025 is calculated as

Basic EPS (A: Aug. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.757-0)/138.720
=-0.02

Lobe Sciences's Basic EPS for the quarter that ended in Feb. 2026 is calculated as

Basic EPS (Q: Feb. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.48-0)/269.487
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.02 mean?
Lobe Sciences (FRA:LOBE) has a EPS (Basic) of €-0.02 as of Feb. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lobe Sciences and its competitors.
Is Lobe Sciences' EPS (Basic) too high?
Lobe Sciences' current EPS (Basic) is €-0.02.
How does Lobe Sciences' EPS (Basic) compare to VRTX and REGN?
Lobe Sciences' EPS (Basic) of €-0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current EPS (Basic) is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (FRA:LOBE) has a current EPS (Basic) of €-0.02. The current EPS (Basic) is €-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lobe Sciences (FRA:LOBE), the current EPS (Basic) is €-0.02 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBEF:USALOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.